Umbralisib shows early promise for patients with marginal zone lymphoma

(American Association for Cancer Research) The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according to early results from the UNITY-NHL phase II clinical trial, which were presented at the AACR Annual Meeting 2019, March 29-April 3.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news